Curated News
By: NewsRamp Editorial Staff
July 03, 2024
Biotech Breakthrough: Cingulate Receives FDA Clearance for Lead Candidate
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Cingulate just received FDA clearance for its new drug, giving them a significant advantage in the biotech industry.
- Cingulate's proprietary technology, Precision Timed Release™, allows a single pill to contain multiple doses of a drug, reducing pill burden for chronic condition patients.
- Cingulate's new drug and technology aim to improve the treatment of underserved conditions, ultimately making life better for those with chronic illnesses.
- Cingulate's development of Precision Timed Release™ technology is an innovative approach to drug delivery, addressing the burden on chronic condition patients.
Impact - Why it Matters
This news matters because it highlights a significant milestone for Cingulate in their efforts to improve treatment for underserved conditions. The FDA clearance for CTx-1301 could have a positive impact on patients with chronic conditions, reducing the pill burden they experience.
Summary
Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions, and has developed a proprietary technology called Precision Timed Release™ (PTR™) which allows a single pill to contain multiple doses of a drug. The company was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Biotech Breakthrough: Cingulate Receives FDA Clearance for Lead Candidate
